StockIQpro
NASDAQ:SION

Sionna Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Sionna Therapeutics, Inc. reported net income of −$75.3M in fiscal 2025. Free cash flow was −$66.7M, and the diluted share count rose 935.6%.Summary generated from Sionna Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 2, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−105.2%
Debt / equityn/a
Free cash flow−$66.7M
FCF marginn/a
Share count change+935.6%

Financials

Fiscal years, $M
Item20242025
Revenuen/an/a
Operating income−71−89
Net income−62−75
Free cash flow−53−67

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations